members are anchored in the mitochondrial outer membrane, and anti-apoptotic family members such as Bcl-2 and Bcl-x L form ion channels which increase the rate of proton extrusion from mitochondria.
Some studies have begun to address the transcriptional regulation of anti-apoptotic Bcl-2 genes. In leukaemias, for example, a hybrid transcription factor formed by chromosomal rearrangement increases Bcl-2 expression, 4 and overexpression of the CCAAT enhancer binding protein, GADD153, reduces Bcl-2 expression with an accompany- ing increase in apoptosis. 5 In neuronal cells, transactivation of Bcl-2 by the POU factor, Brn-3a, is inhibited by p53, although p53 itself has little effect on basal Bcl-2 expression.
6 NF-kB-dependent enhancement of Bcl-x L expression has been reported to mediate survival signals transduced through CD40 in B cells, 7 and the transcriptional repressor, Btf, which induces apoptosis, is normally retained in the cytoplasm by Bcl-2 and Bcl-x L . 8 In the heart, there is also evidence that apoptosis following ischaemia/reperfusion (IR) injury is associated with modulation of Bcl-2 and Bcl-x L expression. For example, in the isolated perfused rat heart, IR reduces Bcl-2 expression, in parallel with increased AP-1 and reduced NF-kB. 9 Moreover, the reduction in apoptosis in IR rabbit hearts produced by phenylephrine preconditioning is associated with an increased Bcl-x/Bax ratio. 10 Since we have observed that activated Signal Transducer and Activator of Transcription (STAT)-1 is an important transactivator in the apoptosis induced by IR injury, 11 and others have shown that STAT-3 is involved in the cardioprotective actions of cardiotrophin-1 (CT-1), 12 we have studied whether these pro-and anti-apoptotic effects of STATs-1 and 3 are mediated by regulation of the expression of the Bcl-2 and Bcl-x L genes.
In U3A-ST1 cells constitutively expressing STAT-1 (Figure 1a) , IFNg, a known activator of STAT-1, reduces basal expression of the Bcl-2 promoter. Transfection with STAT-1 by itself also reduces Bcl-2 promoter activity and overexpression of STAT-1 together with IFNg treatment produces a reduction significantly greater than by either STAT-1 or IFNg alone. This presumably reflects phosphorylation of transfected STAT-1 by Janus kinases activated by ligation of the IFNg receptor. Figure 1a also shows that IFNg reduces basal activity of the Bcl-x promoter; although the reduction in Bcl-x promoter activity produced by STAT-1 overexpression alone is less pronounced than with the Bcl-2 promoter, it is still significant, and IFNg treatment of STAT-1 overexpressing cells again results in more profound reduction in Bcl-x promoter activity than IFNg or STAT-1 alone. The reduction by IFNg in Bcl-2 and Bcl-x promoter activity is not seen in the STAT-1 deficient cell line U3A, indicating that it is dependent on activation of STAT-1. Moreover, expressing STAT-1 alone or together with IFNg treatment does reduce activity of both promoters, indicating that the effect of IFNg can be restored by expressing STAT-1 in the STAT-1 deficient cells ( Figure  1b) . Figure 1c shows that CT-1, a STAT-3 activator, can enhance Bcl-2 and Bcl-x activity. Moreover, CT-1 reverses the suppressive effect of IFNg on the Bcl-2 and Bcl-x promoters (Figure 1c , bars e and f), most markedly in the STAT-1 deficient cell line (Figure 1d ). In the STAT-1 deficient cells, both STAT-3 and CT-1 individually enhance Bcl-2 and Bcl-x promoter activity, and CT-1 also has this effect in STAT-1 expressing cells. The combined effects of STAT-3 and CT-1 are again greater than either factor alone.
The data suggest that one mechanism by which STAT-1 mediates IR-induced apoptosis is by reducing expression of anti-apoptotic Bcl-2 and Bcl-x genes. In addition, the cardioprotective effects of CT-1 may be mediated by STAT-3 induced increases in expression of these genes. STAT-1 and STAT-3 homodimers activate distinct sets of genes. In addition, STAT-1 and STAT-3 can also form heterodimers. 13 The results reported here suggest that, in the heart, the relative proportions of STAT-1 and STAT-3 may affect the transcriptional activity of two anti-apoptotic genes. It is unclear whether STAT-1 and STAT-3 act at a single site to regulate the Bcl-2 and Bcl-x promoters, or whether interaction between separate binding regions is involved. Promoter mapping studies are in progress to resolve this question.
